Hybio Pharmaceutical (300199.SZ): HY3003 Injection Receives Drug Clinical Trial Approval

date
17:10 19/11/2026
avatar
GMT Eight
Hybio Pharmaceutical (300199.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HY3003 Injection. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist in the company's pipeline. The project adopts a multi-dosage-form parallel development strategy, with development directions including HY3003 Injection (weekly formulation), HY3003 sustained-release injection (monthly formulation), and HY3003 tablets (once-daily oral formulation). The HY3003 Injection that received clinical trial approval this time is administered via subcutaneous injection once weekly and is intended for the indication of weight management in adults.
Hybio Pharmaceutical (300199.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" for HY3003 Injection issued upon review and approval by the National Medical Products Administration. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist in the company's pipeline. The project adopts a parallel multi-dosage-form development strategy, with development directions including HY3003 Injection (weekly formulation), HY3003 sustained-release injection (monthly formulation), and HY3003 tablets (once-daily oral formulation). The HY3003 Injection approved for clinical trial this time is administered via subcutaneous injection once weekly and is intended for the indication of weight management in adults.